Almac announced the launch of Biomarkers for biopharma; a range of solutions specifically designed to meet the needs of the biopharma industry. Almac’s solutions are to support biopharma companies in adopting biomarker strategies to enable them to better understand their drug, improve their drug’s success rate, improve the drug’s value and ultimately maximise their drug’s potential.
The use of biomarkers can add substantial value to a compound in development and the ability to identify those patients most likely to respond to a therapy greatly increases the chances of success and the licensing potential of the drug.
Biomarkers for biopharma solutions include pharmacodynamic solutions, patient selection markers, assay development and bioinformatics/biostatistics consultancy.
Professor Paul Harkin, president and managing director, Almac’s diagnostics division, said: “With Biomarkers for biopharma, we have combined a range of key solutions which are ideally suited to growing biopharma companies. For these companies, it is of critical importance that they maximise the potential success of the drugs in their pipeline and the incorporation of a biomarker strategy enables them to do this.”
Almac support and guide companies, enabling biomarker strategies that will maximise their drugs and business’s potential.
The Almac Group comprises five closely integrated divisions offering a broad range of services from R&D, biomarker discovery and development, API manufacture, formulation development, clinical trial supply and technology (IVRS & Web), to commercial-scale manufacture. Almac provides services to more than 600 companies, including all the world leaders in the pharmaceutical and biotech sectors.